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Global investigation and meta-analysis of
the C9orf72 (G4C2)n repeat in
Parkinson disease
ABSTRACT
Objectives: The objective of this study is to clarify the role of (G4C2)n expansions in the etiology of
Parkinson disease (PD) in the worldwide multicenter Genetic Epidemiology of Parkinson’s Disease
(GEO-PD) cohort.
Methods: C9orf72 (G4C2)n repeats were assessed in a GEO-PD cohort of 7,494 patients diag-
nosed with PD and 5,886 neurologically healthy control individuals ascertained in Europe, Asia,
North America, and Australia.
Results: A pathogenic (G4C2)n.60 expansion was detected in only 4 patients with PD (4/7,232;
0.055%), all with a positive family history of neurodegenerative dementia, amyotrophic lateral
sclerosis, or atypical parkinsonism, while no carriers were detected with typical sporadic or famil-
ial PD. Meta-analysis revealed a small increase in risk of PD with an increasing number of (G4C2)n
repeats; however, we could not detect a robust association between the C9orf72 (G4C2)n repeat
and PD, and the population attributable risk was low.
Conclusions: Together, these findings indicate that expansions in C9orf72 do not have a major
role in the pathogenesis of PD. Testing for C9orf72 repeat expansions should only be considered
in patients with PD who have overt symptoms of frontotemporal lobar degeneration/amyotrophic
lateral sclerosis or apparent family history of neurodegenerative dementia or motor neuron
disease. Neurology® 2014;83:1906–1913
GLOSSARY
ALS 5 amyotrophic lateral sclerosis; FTLD 5 frontotemporal lobar degeneration; GEO-PD 5 Genetic Epidemiology of
Parkinson’s Disease; PD 5 Parkinson disease; RP 5 repeat-primed; STR 5 short tandem repeat.
A substantial number of patients with frontotemporal lobar degeneration (FTLD)/amyotrophic
lateral sclerosis (ALS) (14%–35%) carrying C9orf72 (G4C2).60 expansions1–3 present with
atypical parkinsonism in early disease stages and increased incidence of parkinsonism with or
without features of the FTLD/ALS complex in their relatives.4–9 Ten research groups have
reported on C9orf72 repeat expansions in Parkinson disease (PD) or atypical parkinsonism
patients10–19 but none of these investigated the C9orf72 repeat in large-scale cohorts, and Euro-
pean and Australian populations were underrepresented in the published data. Apart from the
pathogenicity of (G4C2).60 expansions, we provided in vitro evidence that the (G4C2) repeat
size negatively correlated with the transcriptional activity of the C9orf72 promoter.20 Hence, it is
conceivable that an increasing number of C9orf72 repeats may affect transcription gradually and
increase susceptibility to disease.20 Three studies indicated a role of C9orf72 repeats in PD
susceptibility but associations were found using different dichotomizations of repeat length,
muddling biological interpretation. In one study, a marginal increased risk of PD was observed
for carriers of (G4C2)10 repeats.12 In the second, a significant increased frequency of (G4C2).20
repeats was observed in patients clinically diagnosed with PD.15 In the third study, the authors
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reported association of (G4C2)$7 repeats with
PD in the Chinese Han population.16 All of
these studies, however, were executed in eth-
nically distinct and medium scaled cohorts.
We set out to clarify the role of the C9orf72
(G4C2)n repeat in PD etiology in the first
global multicenter study cohort of more than
7,000 patients with PD of 12 nationalities and
4 continents. First, we assess the global prev-
alence of pathogenic (G4C2).60 expansions.
Second, the size of the combined study pop-
ulations enables a detailed investigation of the
specific C9orf72 repeat allele or size threshold
associated with increased risk of PD.
METHODS Standard protocol approvals, registrations,
and patient consents. Genetic studies applied in this research
were approved by the ethics committees of the ZNA (Hospital
Network Antwerp), the Antwerp University Hospital, and Uni-
versity of Antwerp. Clinical protocols were approved by the ethics
committees of the ZNA, the Antwerp University Hospital, and
local ethical review boards of the participating research centers.
All human biological samples were collected, fulfilling ethical
approvals, and used in accordance with the terms of subjects’
written informed consent.
Participants. The Genetic Epidemiology of Parkinson’s Dis-
ease (GEO-PD) Consortium includes investigators from 60 sites
from 30 countries and 6 continents (http://www.GEO-PD.org/
about/). All sites were invited to participate in this study. A
total of 18 sites representing 12 countries and 4 continents
contributed either DNA or genotypic data, and clinical data of
in total 15,123 individuals (tables 1 and 2). After thorough
quality control as described in the procedures section below,
13,669 samples were included in this study. We excluded all
duplicate samples, sex mismatches, and samples that failed in
the DNA fingerprint analysis because of low quantity or
quality of DNA or because of contamination of the sample.
Demographics and diagnostic criteria of each series included in
this study and the sample size breakdown from each site are
provided in table 2. Controls were collected at the local sites as
demographically matched neurologically healthy individuals.
Procedures. Sample quality control. Concentration and purity
were checked spectrophotometrically using the Trinean Drop-
Sense96 UV/VIS droplet reader (Trinean, Gentbrugge, Belgium)
for all consortium genomic DNA samples. Sex and DNA finger-
print were determined for all samples using an in-house–developed
multiplex PCR panel composed of 13 short tandem repeat (STR)
markers distributed over multiple autosomal locations: D20S480,
D22S1174, D3S1287, D3S1744, D3S1764, D7S672, D7S2426,
D8S1746, D14S1005, D20S866, D10S1237, D20S912, and
D6S965. This panel also includes a marker specific for the X chro-
mosome (DXS1187) and one for the SRY gene on the Y chromo-
some, and enables fast and accurate sample identification and sex
determination in a single assay. After selective amplification of
20 ng genomic DNA, amplification products were size separated
on an ABI 3730 automatic sequencer (Applied Biosystems,
Foster City, CA) using GeneScan-600 LIZ (Applied Biosystems)
as internal size standard and genotypes were assigned using
in-house–developed TracI genotyping software (http://www.
vibgeneticservicefacility.be).
Genetic analyses. To screen the GEO-PD cohorts for the
pathogenic (G4C2).60 C9orf72 repeat expansion, we designed a
2-step procedure: an STR fragment length assay with flanking
PCR primers optimized for alleles with high GC content
(STR-PCR) followed by 2 repeat-primed PCR assays (forward
and reverse RP-PCR) as described earlier.1,20
Four participating research groups performed the genotyping
in their local facilities according to previously published proce-
dures.2,17 For consistent allele scoring of repeat lengths between
GEO-PD groups and accurate interpretation of the repeat length,
we designed a reference DNA set of 14 samples covering a range
of normal repeat sizes that was genotyped by each of these facil-
ities. Furthermore, for 2 of the cohorts, a random set of samples
homozygous for the STR-PCR assay were included in the
RP-PCR analysis at the Antwerp site for independent validation
of the absence of a pathogenic repeat expansion.
Statistical analyses. To investigate the association between
repeat units and PD susceptibility, 3 explorative approaches were
followed, based on (1) allele counts of the distinct repeat sizes, to
determine whether one or more specific repeat sizes were associ-
ated with PD, (2) the total number of repeat units (sum of both
alleles) per individual, and (3) the size of the longest repeat per
individual (maximum allele). Summary statistics were computed
in a random-effects meta-analysis (DerSimonian-Laird)12,21 for
each approach in the rmeta package implemented in the
R environment version 2.15.3. Based on the results obtained in
the above-mentioned analyses, we performed hypothesis-driven
dichotomized genotypic meta-analyses. Details are provided in
the e-Methods on the Neurology® Web site at Neurology.org.
To take into account the number of tests performed (n 5
22), a Bonferroni-corrected 2-sided p value of #0.002 was con-
sidered statistically significant. Population attributable risk of
(G4C2)10, (G4C2)$10, and (G4C2)$17 was estimated using the
epiR package in R. For the meta-analyses, only the cohorts
including both the patients with PD and the controls that were
Andreas Puschmann, PhD
Christer Nilsson, PhD
Gaëtan Garraux, PhD
Mark S. LeDoux, PhD
Ronald F. Pfeiffer, MD
Magdalena Boczarska-
Jedynak, PhD
Grzegorz Opala
Demetrius M. Maraganore,
MD
Sebastiaan Engelborghs,
PhD
Peter Paul De Deyn, PhD
Patrick Cras, PhD
Marc Cruts, PhD
Christine Van Broeckhoven,
DSc
On behalf of the GEO-PD
Consortium
Correspondence to
Prof. Dr. Van Broeckhoven:
christine.vanbroeckhoven@
molgen.vib-ua.be
Supplemental data
at Neurology.org
Table 1 Synopsis of this global GEO-PD study
Patients Controls
(G4C2)>60
Total 4/7,232 1/5,478
Europe 4/4,252 0/3,172
US 1 CA 0/1,261 0/1,313
Asia 0/1,364 1/656
Australia 0/355 0/337
Risk associated
with (G4C2)n
Totala 7,050 5,886
Europe 4,215 3,379
US 1 CA 1,118 1,313
Asia 1,190 660
Australia 527 534
Abbreviations: CA 5 Canada; GEO-PD 5 Genetic Epidemi-
ology of Parkinson’s Disease.
a For the meta-analyses, only the cohorts including both
patients with Parkinson disease and geographically
matched controls that were size-corrected using the ref-
erence panel were included.
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Table 2 Characteristics of the GEO-PD cohorts included in the study
Site PI Country Ethnicity
Controls Patients
% Males % Familial AAO 6 SD
Diagnostic
criteria for PDIn QC OK STR OK 2-step OK In QC OK STR OK 2-step OK
C. Van Broeckhoven Belgium Caucasian 1,119 1,118 1,039 953 593 593 585 569 50 24 63.8 6 13 Gelb26
G. Garraux Belgium Caucasian 0 0 0 0 139 126 125 116 59 NA 60.9 6 10.5 Gelb26
C. Klein Germany Caucasian 706 697 679 581 433 410 396 396 55 33 52.0 6 14.2 Hoehn and Yahr27
A. Deutschländer Germany Caucasian 87 81 79 79 87 81 79 79 57 22 61.5 6 11.3 UKPDBB28
C. Ferrarese Italy Caucasian 92 89 86 86 87 84 68 68 58 20 65.5 6 9.6 Gelb26
E.M. Valente Italy Caucasian 92 83 83 83 92 90 89 89 47 33 52.9 6 5.0 UKPDBB28
G. Annesi Italy Caucasian 100 100 95 95 100 92 74 74 51 0 59.7 6 9.0 Gelb26
G.M. Hadjigeorgiou Greece Caucasian 300 232 223 220 300 269 264 264 50 13 63.3 6 10.4 Bower29
A. Puschmann Sweden Caucasian 43 43 43 43 119 115 111 111 56 49 61.7 6 9.7 Ward and Gibb30
G.D. Mellick Australia Caucasian 920 571 534 337 920 535 527 355 46 27 62.0 6 11.5 Gelb26
M.S. LeDoux US Caucasian 0 0 0 0 184 150 143 143 61 32 60.1 6 11.8 Gelb26
S.J. Chung Korea Asian 650 568 562 558 1,200 1,113 1,088 1,088 46 9 59.0 6 10.0 Gelb26
E.-K. Tan Singapore Asian 200 100 98 98 200 102 102 100 67 8 53.2 6 7.0 UKPDBB28
N. Hattori Japan Asian 69 0 0 0 183 177 176 176 52 2 41.6 6 11.9 Gelb26/Hoehn and Yahr27
R. Krüger/M. Sharma Germany Caucasian 647 625 625 605 1,386 1,367 1,367 1,304 62 NA 49.9 6 17.1 UKPDBB28
S. Lesage France Caucasian 442 442 427 427 1,193 1,185 1,182 1,182 54 39 48.6 6 12.0 UKPDBB28
Z.K. Wszolek US Caucasian 712 712 712 712 676 676 676 676 53 NA 69.2 6 11.1 UKPDBB28
E. Rogaeva Canada Mixed 601 601 601 601 451 442 442 442 50 35 52.4 6 13.7 UKPDBB28
Abbreviations: AAO 5 age at onset; GEO-PD 5 Genetic Epidemiology of Parkinson’s Disease; NA 5 not available; PD 5 Parkinson disease; PI 5 principal investigator; QC 5 quality control; STR 5 short tandem
repeat; UKPDBB 5 UK Parkinson’s Disease Brain Bank.
At the initial quality control step (QC), we excluded all duplicate samples, sex mismatches, and samples that failed in the DNA fingerprint analysis because of low quantity or quality of DNA or because of
contamination of the sample. Additional samples did not pass the 2-step genetic analysis because of DNA shortage or limited concentration of the DNA sample.
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size-corrected based on the reference panel were included in
the study.
RESULTS Definite pathogenic C9orf72 repeat
expansions in PD. A total of 12,710 samples, including
7,232 patients with PD and 5,478 control individu-
als, were successfully genotyped with the 2-step
(G4C2)n repeat genotyping assay. RP-PCR analysis
revealed the typical sawtooth tail pattern indicative
of a pathogenic repeat expansion (G4C2).60 in one
German (MS_RK cohort) (1/1,304; 0.08%) and 3
French (SL cohort) (3/1,182; 0.25%) patients but
none in the other GEO-PD patient cohorts (table 1).
Based on these results, we calculated a prevalence of
pathogenic C9orf72 repeat expansions in this global
consortium cohort of 0.06%.
The German patient was diagnosed with idio-
pathic PD at the age of 57 years. One year after onset,
clinical examination revealed hypomimia, hypokine-
sia, resting tremor of the right arm, minor postural
instability, mild bilateral rigidity, and slowed shuf-
fling gait but also short-term memory disturbances,
social withdrawal, and minor apathy. The patient
had a positive family history of neurodegenerative
dementia. All 3 French patients were diagnosed with
PD without cognitive dysfunction at disease onset,
and a detailed clinical description has been reported
previously.17 Briefly, the first patient developed left
hemiparkinsonism at age 29 years and symptoms
worsened progressively while dopamine agonists were
only partially effective. In the second patient, parkin-
sonism began at age 48 years and a cognitive decline
was noted at age 56 years. The third patient devel-
oped parkinsonism at age 64 years and developed a
mild cognitive deficit at age 69. Although these 3
patients were clinically diagnosed with PD, they all
had family histories of atypical parkinsonism, degen-
erative dementias, or ALS. No expansions were de-
tected in patients with sporadic PD or patients with a
familial history of PD. Moreover, mutations in
known PD genes had previously been excluded in
these 4 pathogenic expansion carriers.
We identified one Asian control of Chinese origin
with an age at inclusion of 52 years carrying a patho-
genic (G4C2).60 expansion (table 1). Currently, there
is no record of any symptoms related to PD, FTLD,
or ALS in this individual. This brings the estimated
prevalence of pathogenic repeat expansions in con-
trols to 0.02% (1/5,478). Apart from the expansion
mutations, the distribution of repeat lengths ranged
from 0 to 32 in the Caucasian and from 7 to 14 in the
Asian control persons.
C9orf72 repeat and PD susceptibility. We investigated
the role of (G4C2)n repeats in risk of PD. First, we
assessed the distribution of the alleles in patients with
PD vs controls in the GEO-PD cohort (figure 1). The
frequencies of the (G4C2)10 allele and of (G4C2)$17
were nominally increased in PD vs the controls but
the differences were not statistically significant after
Bonferroni correction (figure 1, table 3, figure e-1, A
and B). Genotypic frequencies for (G4C2)10 (table 3,
figure e-1, C) and (G4C2)$17 (table 3, figure e-1, D)
were not significantly different between patients and
controls after correction for multiple testing. The
estimated attributable fractions in the population
are very low (table 3). When considering the sum
of the alleles and the size of the maximum allele as
a quantitative variable, we observed a small but
significant increase of disease risk with a rising
number of repeat units (sum of alleles p 5 0.0012,
summary effect [b] 5 0.0128 [0.00504–0.0205],
figure e-2, A; maximum allele p 5 0.0010,
summary effect [b] 5 0.0181 [0.00731–0.029],
figure e-2, B). Together, these results suggested that
the risk effect may not only be linked to the (G4C2)10
repeat but may be increasing with length while the
effect in the larger alleles is probably masked by the
small number of carriers. Therefore, we decided to
analyze the risk effect of C9orf72 repeat expansions as
a binary categorical value with a cutoff between 9 and
10. However, neither allelic nor genotypic meta-
analysis of the GEO-PD cohorts revealed significant
association with PD for (G4C2)$10 repeat alleles after
Bonferroni correction (table 3, figure e-3, A and B).
Furthermore, the estimated population attributable
risk is low (table 3).
DISCUSSION Molecular reclassification of complex
brain diseases based on genetic etiology is of utmost
importance to improve differential diagnosis and to
rationalize drug development. Assessment of the con-
tribution of novel disease genes to clinically and path-
ologically overlapping diseases is instrumental in this
reclassification. In this global study, we assessed the
prevalence of (G4C2)n repeat alleles and expansions
in an extended PD cohort ascertained within the
GEO-PD Consortium and excluded a major role for
pathogenic (G4C2).60 repeat expansions in the
causation of PD. The low frequency of these
expansions (0.06%) in the GEO-PD cohort is in
agreement with earlier findings in distinct patient
groups10–15,18,19 and falls in the range of frequencies
observed in controls by us (0.02%) and others (0–
0.6%).1–4,22 Furthermore, 75% of the pathogenic
expansion carriers in this global study showed a decline
in cognitive functions within 1 to 8 years after onset. In
the absence of autopsy diagnoses, we therefore cannot
exclude that some if not all of these expansion carriers are
primarily FTLD/ALS patients with pronounced early
parkinsonian symptoms or comorbidity of PD and
FTLD/ALS. This hypothesis is supported by the
identification of only one pathogenic mutation carrier
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in 826 (0.1%) autopsy-confirmed PD cases.23,24 Of
note, this carrier presented, in addition to Lewy
body pathology, with frontotemporal degeneration
and C9orf72-ALS/FTLD pathology with numerous
p62-positive inclusions. Furthermore, although
substantia nigra involvement is common in
C9orf72-positive ALS, it can be clearly distinguished
from PD-related mechanisms by the presence of p62-
positive inclusion and absence of Lewy body
pathology.24
Altogether, it is not advisable to include C9orf72
(G4C2)n repeat expansion testing in a medical genetic
diagnostic setting for typical PD patients. Exceptions
can be made for patients with PD who have cognitive
and/or behavioral deficits early in the disease process or in
patients with a personal or familial history of FTLD/ALS.
Given differences in the existing literature on
C9orf72 (G4C2)n repeat length as risk factor for
PD,12,15,16 we used the size of this global cohort to
estimate a PD-related threshold of C9orf72 repeats.
Calculation of the risk for each of the observed
C9orf72 (G4C2)n alleles in the GEO-PD cohorts sug-
gested a role for the 10-units repeat and for the pooled
alleles of 17 units or more in PD susceptibility. Gen-
otypic meta-analysis supported a possible link
between (G4C2)10 and increased risk of PD but the
association did not reach significance after correction
for multiple testing. In addition, the number of car-
riers of these intermediate alleles is small and one
should be cautious with the interpretation of these
results. Furthermore, it is difficult to envisage the
biological relevance of risk associated with a single
Figure 1 Overall distribution of C9orf72 repeat alleles in the GEO-PD cohorts
Only cohorts including both patients with PD and controls that were size-corrected based on the reference panel were included in the study. When the high-
est count for a specific allele was 5 or less across cohorts, the allele was clumped with the next allele for each cohort. (A) Allele frequencies. The p values for
individual alleles were calculated using a Dersimonian-Laird random-effect meta-analysis. (B) Allele counts. *Nominally significant p values. Con 5 controls;
GEO-PD 5 Genetic Epidemiology of Parkinson’s Disease; PD 5 Parkinson disease.
1910 Neurology 83 November 18, 2014
allele. Of note, we observed a small but significant
increase in risk with an accumulative number of re-
peats supporting the idea of a threshold size rather
than a single allele as the culprit of increased risk. We
therefore decided to study the combined effect of
(G4C2) alleles of 10 units and larger in the global
GEO-PD cohort. Although meta-analyses implicated
a potential role for these intermediate-sized repeats in
PD risk, none of the associations survived Bonferroni
correction suggesting that if C9orf72 repeats of 10
units or larger have a role in PD susceptibility, the
effect is small. This is supported by the fact that none
of the published genome-wide association studies re-
vealed the C9orf72 locus as a risk factor for PD.25 A
limitation of this study is that we did not yet include
all published association studies of C9orf72 in PD;
however, we chose to include only those studies that
were corrected for allele scoring bias based on a ref-
erence panel.
Altogether, these data support the current hypoth-
esis that pathogenic (G4C2)n repeat expansions in
C9orf72 appear to be specific for the FTLD/ALS
spectrum with little or no contribution to the wider
spectrum of movement disorders. It will be of interest
to study the role of intermediate repeats$10 units in
other neurodegenerative disorders, however, to obtain
a more profound knowledge on their role in neuro-
degenerative diseases and a better understanding of
the underlying mechanism.
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